NCT00072085已完成2 期
Immunization Of Patients With Metastatic Melanoma Using A Recombinant GP100 Protein (184V) And A Class I Restricted Peptide From The GP100 Antigen
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying immunization using two different gp100 protein vaccines to compare how well they work in treating patients with metastatic melanoma.
详细描述
OBJECTIVES:
Primary
- Compare the clinical response in patients with metastatic melanoma immunized with recombinant gp100 protein (184V) emulsified in Montanide ISA-51 with or without gp100:209-217 (210M) peptide.
Secondary
- Compare the toxicity profile of these immunizations in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Vaccine Therapy in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00019994National Cancer Institute (NCI)
已完成
2 期
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic MelanomaMelanoma (Skin)NCT00019383National Cancer Institute (NCI)
已完成
2 期
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00054535National Cancer Institute (NCI)
已完成
2 期
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00019669National Cancer Institute (NCI)
已完成
2 期
Vaccine Therapy in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00019734National Cancer Institute (NCI)